Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
J Infect Dis ; 229(6): 1702-1710, 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38213276

ABSTRACT

Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To better understand the mechanism of action of CCP, we studied viral replication and disease progression in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected hamsters treated with CCP obtained from recovered COVID-19 patients that were also vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. Vaxplas transiently enhanced disease severity and lung pathology in hamsters treated near peak viral replication due to immune complex and activated complement deposition in pulmonary endothelium, and recruitment of M1 proinflammatory macrophages into the lung parenchyma. However, aside from one report, transient enhanced disease has not been reported in CCP recipient patients, and the transient enhanced disease in Vaxplas hamsters may have been due to mismatched species IgG-FcR interactions, infusion timing, or other experimental factors. Despite transient disease enhancement, Vaxplas dramatically reduced virus replication in lungs and improved infection outcome in SARS-CoV-2-infected hamsters.


Subject(s)
Antibodies, Viral , COVID-19 Serotherapy , COVID-19 Vaccines , COVID-19 , Immunization, Passive , Lung , SARS-CoV-2 , Virus Replication , Animals , COVID-19/immunology , COVID-19/virology , SARS-CoV-2/immunology , Cricetinae , Lung/virology , Lung/immunology , Lung/pathology , Antibodies, Viral/blood , Antibodies, Viral/immunology , COVID-19 Vaccines/immunology , COVID-19 Vaccines/administration & dosage , Humans , Mesocricetus , Disease Models, Animal , Male , Female
2.
bioRxiv ; 2023 Aug 23.
Article in English | MEDLINE | ID: mdl-37662344

ABSTRACT

The utility of COVID-19 convalescent plasma (CCP) for treatment of immunocompromised patients who are not able to mount a protective antibody response against SARS-CoV-2 and who have contraindications or adverse effects from currently available antivirals remains unclear. To better understand the mechanism of protection in CCP, we studied viral replication and disease progression in SARS-CoV-2 infected hamsters treated with CCP plasma obtained from recovered COVID patients that had also been vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. We found that Vaxplas dramatically reduced virus replication in the lungs and improved infection outcome in SARS-CoV-2 infected hamsters. However, we also found that Vaxplas transiently enhanced disease severity and lung pathology in treated animals likely due to the deposition of immune complexes, activation of complement and recruitment of increased numbers of macrophages with an M1 proinflammatory phenotype into the lung parenchyma.

3.
Microbiol Spectr ; 9(3): e0139721, 2021 12 22.
Article in English | MEDLINE | ID: mdl-34817208

ABSTRACT

Human clinical studies investigating use of convalescent plasma (CP) for treatment of coronavirus disease 2019 (COVID-19) have produced conflicting results. Outcomes in these studies may vary at least partly due to different timing of CP administration relative to symptom onset. The mechanisms of action of CP include neutralizing antibodies but may extend beyond virus neutralization to include normalization of blood clotting and dampening of inflammation. Unresolved questions include the minimum therapeutic titer in the CP units or CP recipient as well as the optimal timing of administration. Here, we show that treatment of macaques with CP within 24 h of infection does not reduce viral shedding in nasal or lung secretions compared to controls and does not detectably improve any clinical endpoint. We also demonstrate that CP administration does not impact viral sequence diversity in vivo, although the selection of a viral sequence variant in both macaques receiving normal human plasma was suggestive of immune pressure. Our results suggest that CP, administered to medium titers, has limited efficacy, even when given very early after infection. Our findings also contribute information important for the continued development of the nonhuman primate model of COVID-19. These results should inform interpretation of clinical studies of CP in addition to providing insights useful for developing other passive immunotherapies and vaccine strategies. IMPORTANCE Antiviral treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain very limited. One treatment that was explored beginning early in the pandemic (and that is likely to be tested early in future pandemics) is plasma collected from people who have recovered from coronavirus disease 2019 (COVID-19), known as convalescent plasma (CP). We tested if CP reduces viral shedding or disease in a nonhuman primate model. Our results demonstrate that administration of CP 1 day after SARS-CoV-2 infection had no significant impact on viral loads, clinical disease, or sequence diversity, although treatment with normal human plasma resulted in selection of a specific viral variant. Our results demonstrate that passive immunization with CP, even during early infection, provided no significant benefit in a nonhuman primate model of SARS-CoV-2 infection.


Subject(s)
COVID-19/therapy , Immunization, Passive/methods , SARS-CoV-2 , Animals , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antiviral Agents/therapeutic use , COVID-19/immunology , Disease Models, Animal , Humans , Immunity , Lung/pathology , Macaca mulatta , Pandemics , Spike Glycoprotein, Coronavirus/immunology , Viral Load , Virus Replication
4.
Nat Commun ; 12(1): 541, 2021 01 22.
Article in English | MEDLINE | ID: mdl-33483492

ABSTRACT

CD4 T follicular helper (Tfh) cells are important for the generation of durable and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates Tfh cells and stimulates the germinal center (GC) response is an important question as we investigate vaccine induced immunity against COVID-19. Here, we report that SARS-CoV-2 infection in rhesus macaques, either infused with convalescent plasma, normal plasma, or receiving no infusion, resulted in transient accumulation of pro-inflammatory monocytes and proliferating Tfh cells with a Th1 profile in peripheral blood. CD4 helper cell responses skewed predominantly toward a Th1 response in blood, lung, and lymph nodes. SARS-CoV-2 Infection induced GC Tfh cells specific for the SARS-CoV-2 spike and nucleocapsid proteins, and a corresponding early appearance of antiviral serum IgG antibodies. Collectively, the data show induction of GC responses in a rhesus model of mild COVID-19.


Subject(s)
COVID-19/immunology , Germinal Center/immunology , SARS-CoV-2/immunology , T Follicular Helper Cells/immunology , Th1 Cells/immunology , Animals , Antibodies, Viral/blood , COVID-19/therapy , Cell Line , Chlorocebus aethiops , Coronavirus Nucleocapsid Proteins/immunology , Disease Models, Animal , Female , Humans , Immunity, Humoral/immunology , Immunization, Passive , Immunogenicity, Vaccine/immunology , Immunoglobulin G/blood , Macaca mulatta , Male , Phosphoproteins/immunology , SARS-CoV-2/isolation & purification , Spike Glycoprotein, Coronavirus/immunology , Vero Cells , COVID-19 Serotherapy
5.
bioRxiv ; 2020 Jul 08.
Article in English | MEDLINE | ID: mdl-32676606

ABSTRACT

CD4 T follicular helper (T fh ) cells are important for the generation of long-lasting and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates T fh cells and stimulates the germinal center response is an important question as we investigate vaccine options for the current pandemic. Here we report that, following infection with SARS-CoV-2, adult rhesus macaques exhibited transient accumulation of activated, proliferating T fh cells in their peripheral blood on a transitory basis. The CD4 helper cell responses were skewed predominantly toward a T h 1 response in blood, lung, and lymph nodes, reflective of the interferon-rich cytokine environment following infection. We also observed the generation of germinal center T fh cells specific for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, and a corresponding early appearance of antiviral serum IgG antibodies but delayed or absent IgA antibodies. Our data suggest that a vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity.

6.
J Nerv Ment Dis ; 206(12): 950-954, 2018 12.
Article in English | MEDLINE | ID: mdl-30439782

ABSTRACT

This study examined help-seeking behavior from professional, informal, and religious sources in veterans with a probable need for treatment. In total, 93 veterans who screened positive for posttraumatic stress disorder/major depressive disorder completed assessments of help-seeking at two time points spaced apart by 6 months. Less than half (40%) reached out to a mental health professional or physician; only 1 in 10 engaged with providers who specialize in evidence-based therapies to a minimally adequate degree. Although roughly two thirds pursued help from informal sources, less than 10% similarly sought help nine or more times. Veterans with high willingness to seek help from specific sources at baseline were more likely to report sustained engagement in help-seeking behavior along these same lines at follow-up. Assessing veterans' help-seeking intentions may add prognostic value in predicting engagement in services. Veterans may also benefit from tailoring service delivery models according to preferred sources of help in their families and communities.


Subject(s)
Depressive Disorder, Major/psychology , Patient Acceptance of Health Care/statistics & numerical data , Stress Disorders, Post-Traumatic/psychology , Veterans/psychology , Adult , Depressive Disorder, Major/therapy , Female , Help-Seeking Behavior , Humans , Male , Patient Acceptance of Health Care/psychology , Psychiatric Status Rating Scales , Stress Disorders, Post-Traumatic/therapy , Surveys and Questionnaires , United States , Veterans/statistics & numerical data
7.
J Relig Health ; 57(6): 2444-2460, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30094678

ABSTRACT

This study examines VA chaplains' understandings of moral injury (MI) and preferred intervention strategies. Drawing qualitative responses with a nationally-representative sample, content analyses indicated that chaplains' definitions of MI comprised three higher order clusters: (1) MI events, (2) mechanisms in development of MI, and (3) warning signs of MI. Similarly, chaplains' intervention foci could be grouped into three categories: (1) pastoral/therapeutic presence, (2) implementing specific interventions, and (3) therapeutic processes to promote moral repair. Findings are discussed related to emerging conceptualizations of MI, efforts to adapt existing evidence-based interventions to better address MI, and the potential benefits of better integrating chaplains into VA mental health service delivery.


Subject(s)
Clergy/psychology , Mental Health Services/organization & administration , Military Personnel/psychology , Pastoral Care/organization & administration , Stress Disorders, Post-Traumatic/psychology , Veterans/psychology , Adult , Aged , Aged, 80 and over , Humans , Middle Aged , Qualitative Research
8.
J Infect Dis ; 218(1): 124-132, 2018 06 05.
Article in English | MEDLINE | ID: mdl-29701813

ABSTRACT

Background: New methods to increase measles and rubella (MR) vaccination coverage are needed to achieve global and regional MR elimination goals. Methods: Here, we developed microneedle (MN) patches designed to administer MR vaccine by minimally trained personnel, leave no biohazardous sharps waste, remove the need for vaccine reconstitution, and provide thermostability outside the cold chain. This study evaluated the immunogenicity of MN patches delivering MR vaccine to infant rhesus macaques. Results: Protective titers of measles neutralizing antibodies (>120 mIU/mL) were detected in 100% of macaques in the MN group and 75% of macaques in the subcutaneous (SC) injection group. Rubella neutralizing antibody titers were >10 IU/mL for all groups. All macaques in the MN group were protected from challenge with wild-type measles virus, whereas 75% were protected in the SC group. However, vaccination by the MN or SC route was unable to generate protective immune responses to measles in infant macaques pretreated with measles immunoglobulin to simulate maternal antibody. Conclusions: These results show, for the first time, that MR vaccine delivered by MN patch generated protective titers of neutralizing antibodies to both measles and rubella in infant rhesus macaques and afforded complete protection from measles virus challenge.


Subject(s)
Drug Delivery Systems/instrumentation , Measles Vaccine/administration & dosage , Measles Vaccine/immunology , Measles/prevention & control , Rubella Vaccine/administration & dosage , Rubella Vaccine/immunology , Rubella/prevention & control , Administration, Cutaneous , Animals , Animals, Newborn , Antibodies, Neutralizing/blood , Female , Macaca mulatta , Male
9.
J Infect Dis ; 218(6): 856-867, 2018 08 14.
Article in English | MEDLINE | ID: mdl-29701840

ABSTRACT

Background: Influenza A virus (IAV) vaccines offer little protection from mismatched viruses with antigenically distant hemagglutinin (HA) glycoproteins. We sought to determine if a cationic lipid/DNA complex (CLDC) adjuvant could induce heterosubtypic protection if added to a whole inactivated IAV vaccine (WIV). Methods: Adult rhesus macaques (RMs) were vaccinated and at 2 weeks boosted with either an H1N1-WIV or an H3N2-WIV, with and without CLDC adjuvant. Four weeks postboost, animals were challenged with an H1N1 IAV matched to the H1N1-WIV vaccine. Results: After challenge, viral RNA (vRNA) levels in the trachea of control RMs and RMs vaccinated with the unadjuvanted H1 or H3 WIV vaccines were similar. However, vRNA levels in the trachea of both the H1-WIV/CLDC- and the H3-WIV/CLDC-vaccinated RMs (P < 0.01 and P < 0.05, respectively) were significantly lower than in unvaccinated control RMs. Heterosubtypic protection in H3-WIV/CLDC RMs was associated with significantly higher levels of nucleoprotein (NP) and matrix-1-specific immunoglobulin G antibodies (P < 0.05) and NP-specific nonneutralizing antibody-dependent natural killer cell activation (P < 0.01) compared with unprotected H3-WIV RMs. Conclusions: Addition of the CLDC adjuvant to a simple WIV elicited immunity to conserved virus structural proteins in RMs that correlate with protection from uncontrolled virus replication after heterosubtypic influenza virus challenge.


Subject(s)
DNA/administration & dosage , Influenza A Virus, H1N1 Subtype/physiology , Influenza A Virus, H3N2 Subtype/physiology , Influenza Vaccines/administration & dosage , Lipids/administration & dosage , Orthomyxoviridae Infections/prevention & control , Vaccines, Attenuated/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Disease Models, Animal , Female , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/pharmacology , Liposomes/administration & dosage , Macaca mulatta/immunology , Macaca mulatta/virology , Male , Nucleocapsid Proteins , Orthomyxoviridae Infections/immunology , Plasmids/genetics , RNA-Binding Proteins/immunology , Trachea/virology , Vaccines, Attenuated/pharmacology , Viral Core Proteins/immunology , Virus Replication/drug effects
10.
J Health Care Chaplain ; 23(3): 113-129, 2017.
Article in English | MEDLINE | ID: mdl-28358243

ABSTRACT

A mixed method design was implemented to examine the spirituality and emotional well-being of Veterans Health Administration (VHA) chaplains and how potential changes in spirituality and emotional well-being may affect their professional quality of life. Four distinct categories of changes emerged from the narrative statements of a nationally representative sample of 267 VHA chaplains: (1) positive changes (e.g., increased empathy), (2) negative changes (e.g., dysthymic mood, questioning religious beliefs), (3) combination of positive and negative changes, and (4) no change (e.g., sustenance through spirituality or self-care). Most chaplains reported positive (37%) or no change (30%) in their spirituality and/or emotional well-being. However, quantitative analyses revealed that chaplains who reported negative changes endorsed greater burnout and secondary traumatic stress. Overall, these findings suggest VHA chaplains are predominantly spiritually resilient, but negative changes in the spiritual domain can occur, potentially increasing the risk of adverse changes in professional quality of life.


Subject(s)
Clergy/psychology , Quality of Life/psychology , Spirituality , Burnout, Professional , Clergy/statistics & numerical data , Compassion Fatigue , Empathy , Female , Humans , Male , Middle Aged , Qualitative Research , Resilience, Psychological , United States , United States Department of Veterans Affairs
11.
Psychol Trauma ; 9(5): 583-586, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28080076

ABSTRACT

OBJECTIVE: Adverse childhood experiences (ACEs) are associated with increased risk for suicide and appear to occur in disproportionately high rates among men who served in the U.S. military. However, research has yet to examine a comprehensive range of ACEs among Iraq/Afghanistan veterans with combat-related posttraumatic stress disorder (PTSD) or whether these premilitary stressors may contribute to suicidal behavior in this highly vulnerable population. METHOD: A sample of 217 men entering a residential program for combat-related PTSD completed measures for ACEs, combat exposure, and lifetime suicidal ideation and attempts. RESULTS: The majority of patients had experienced multiple types of adversity or traumas during childhood/adolescence. In particular, 83.4% endorsed at least 1 ACE category and 41.5% reported experiencing 4 or more ACEs. When accounting for effects of deployment-related stressors, we further found that accumulation of ACEs was uniquely linked with thoughts of suicide or attempts among these patients. Namely, for every 1-point increase on the ACE Questionnaire, veterans' risk of suicidal ideation and attempts increased by 23% and 24%, respectively. CONCLUSION: This brief report provides initial evidence that veterans seeking treatment for combat-related PTSD often have extensive histories of premilitary stressors that may increase suicide risk beyond probable deployment-related traumas. (PsycINFO Database Record


Subject(s)
Adult Survivors of Child Abuse , Stress Disorders, Post-Traumatic/therapy , Suicidal Ideation , Suicide, Attempted , Veterans , Adult , Adult Survivors of Child Abuse/psychology , Afghan Campaign 2001- , Humans , Iraq War, 2003-2011 , Logistic Models , Male , Patient Acceptance of Health Care/psychology , Risk Factors , Stress Disorders, Post-Traumatic/epidemiology , Stress Disorders, Post-Traumatic/psychology , Veterans/psychology
12.
J Infect Dis ; 209(1): 24-33, 2014 Jan 01.
Article in English | MEDLINE | ID: mdl-24141979

ABSTRACT

BACKGROUND: The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates. METHODS: Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1). RESULTS: We found that elderly macaques have significantly lower levels of circulating naive CD4(+) T cells, naive CD8(+) T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P < .001) and immunoglobulin A (P < .001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P < .01) relative to the unvaccinated control animals. CONCLUSIONS: These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.


Subject(s)
Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Orthomyxoviridae Infections/prevention & control , Aging/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Female , Integrin alpha4/blood , Integrin beta Chains/blood , Interferon-gamma/blood , Macaca mulatta , Male , Nasal Lavage Fluid/virology , Orthomyxoviridae Infections/immunology , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology
13.
J Virol ; 87(2): 1150-8, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23152507

ABSTRACT

Alpha interferon (IFN-α) production is triggered when influenza virus RNA is detected by appropriate pattern recognition receptors in the host cell. IFN-α induces the expression of more than 300 interferon-stimulated genes (ISGs), and this blunts influenza virus replication. The human ISG MxA can inhibit influenza A virus replication in mouse cells by interfering with a step in the virus replication cycle after primary transcription of the negative-strand RNA genome to mRNA (J. Pavlovic, O. Haller, and P. Staeheli, J. Virol. 66:2564-2569, 1992). To determine the role of MxA in blocking human influenza A virus replication in primate cells, we manipulated MxA expression in rhesus kidney epithelial cells (LLC-MK(2)) and human lung carcinoma cells (A549). We found that IFN-α treatment prior to influenza virus infection suppressed virus replication and induced the expression of many ISGs, including MxA. However, IFN-α-mediated suppression of virus replication was abolished by small interfering RNA (siRNA) knockdown of MxA expression in IFN-treated cells. In addition, influenza virus replication was suppressed in Vero cells stably transfected with MxA. A strand-specific reverse transcription-PCR (RT-PCR) assay showed that positive-strand influenza virus mRNA and negative-strand genomic RNA (gRNA) accumulated to high levels at 8 h after infection in control Vero cells containing the empty vector. However, in Vero cells stably transfected with MxA positive-strand influenza virus mRNA, complementary positive-strand influenza virus genome RNA (cRNA) and influenza virus gRNA were drastically suppressed. Thus, in primate cells, MxA inhibits human seasonal influenza virus replication at a step prior to primary transcription of gRNA into mRNA. Taken together, these results demonstrate that MxA mediates control of influenza virus replication in primate cells treated with IFN-α.


Subject(s)
GTP-Binding Proteins/biosynthesis , GTP-Binding Proteins/immunology , Influenza A virus/immunology , Influenza A virus/physiology , Interferon-alpha/immunology , Virus Replication , Animals , Cell Line , Chlorocebus aethiops , Humans , Macaca mulatta , Myxovirus Resistance Proteins , RNA, Viral/metabolism , Transcription, Genetic
14.
J Virol ; 86(13): 7098-106, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22532691

ABSTRACT

No information exists regarding immune responses to human immunodeficiency virus (HIV) infection in the foreskin or glans of the human penis, although this is a key tissue for HIV transmission. To address this gap, we characterized antiviral immune responses in foreskin of male rhesus macaques (RMs) inoculated with simian immunodeficiency virus (SIV) strain SIVmac251 by penile foreskin exposure. We found a complete population of immune cells in the foreskin and glans of normal RMs, although B cells were less common than CD4(+) and CD8(+) T cells. IgG-secreting cells were detected by enzyme-linked immunospot (ELISPOT) assay in cell suspensions made from the foreskin. In the foreskin and glans of SIV-infected RMs, although B cells were less common than CD4(+) and CD8(+) T cells, SIV-specific IgG antibody was present in foreskin secretions. In addition, cytokine-secreting SIV-specific CD8(+) T cells were readily found in cell suspensions made from the foreskin. Although potential HIV target cells were found in and under the epithelium covering all penile surfaces, the presence of antiviral effector B and T cells in the foreskin suggests that vaccines may be able to elicit immunity in this critical site to protect men from acquiring HIV.


Subject(s)
Antibodies, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Foreskin/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Animals , Antibodies, Viral/analysis , B-Lymphocytes/immunology , Cytokines/metabolism , Flow Cytometry , Foreskin/chemistry , Foreskin/pathology , Foreskin/virology , Immunoglobulin G/analysis , Immunoglobulin G/immunology , Immunohistochemistry , Immunophenotyping , Macaca mulatta , Male , Microscopy , Penis/chemistry , Penis/immunology , Penis/pathology , Penis/virology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/virology
15.
PLoS One ; 6(6): e21756, 2011.
Article in English | MEDLINE | ID: mdl-21747924

ABSTRACT

This study sought to define the role of memory lymphocytes in the protection from homologous influenza A virus re-challenge in rhesus macaques. Depleting monoclonal antibodies (mAb) were administered to the animals prior to their second experimental inoculation with a human seasonal influenza A virus strain. Treatment with either anti-CD8α or anti-CD20 mAbs prior to re-challenge had minimal effect on influenza A virus replication. Thus, in non-human primates with pre-existing anti-influenza A antibodies, memory B cells and CD8α⁺ T cells do not contribute to the control of virus replication after re-challenge with a homologous strain of influenza A virus.


Subject(s)
B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/virology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/virology , Influenza A Virus, H1N1 Subtype/physiology , Seasons , Virus Replication/immunology , Animals , Antibodies, Monoclonal/immunology , Antigens, CD20/immunology , B-Lymphocyte Subsets/cytology , CD8 Antigens/immunology , CD8-Positive T-Lymphocytes/cytology , Humans , Immunity, Innate/immunology , Immunization , Influenza A Virus, H1N1 Subtype/immunology , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Macaca mulatta , Species Specificity
16.
Vaccine ; 29(5): 931-40, 2011 Jan 29.
Article in English | MEDLINE | ID: mdl-21111777

ABSTRACT

Venezuelan equine encephalitis virus replicon particles (VRP) without a transgene (null VRP) have been used to adjuvant effective humoral [1], cellular [2], and mucosal [3] immune responses in mice. To assess the adjuvant activity of null VRP in the context of a licensed inactivated influenza virus vaccine, rhesus monkeys were immunized with Fluzone(®) alone or Fluzone(®) mixed with null VRP and then challenged with a human seasonal influenza isolate, A/Memphis/7/2001 (H1N1). Compared to Fluzone(®) alone, Fluzone(®)+null VRP immunized animals had stronger influenza-specific CD4(+) T cell responses (4.4 fold) with significantly higher levels of virus-specific IFN-γ (7.6 fold) and IL-2 (5.3 fold) producing CD4+ T cells. Fluzone(®)+null VRP immunized animals also had significantly higher plasma anti-influenza IgG (p<0.0001, 1.3 log) and IgA (p<0.05, 1.2 log) levels. In fact, the mean plasma anti-influenza IgG titers after one Fluzone(®)+null VRP immunization was 1.2 log greater (p<0.04) than after two immunizations with Fluzone(®) alone. After virus challenge, only Fluzone(®)+null VRP immunized monkeys had a significantly lower level of viral replication (p<0.001) relative to the unimmunized control animals. Although little anti-influenza antibody was detected in the respiratory secretions after immunization, strong anamnestic anti-influenza IgG and IgA responses were present in secretions of the Fluzone(®)+null VRP immunized monkeys immediately after challenge. There were significant inverse correlations between influenza RNA levels in tracheal lavages and plasma anti-influenza HI and IgG anti-influenza antibody titers prior to challenge. These results demonstrate that null VRP dramatically improve both the immunogenicity and protection elicited by a licensed inactivated influenza vaccine.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Drug Carriers , Encephalitis Virus, Venezuelan Equine/genetics , Genetic Vectors , Influenza Vaccines/immunology , Animals , Antibodies, Viral/blood , CD4-Positive T-Lymphocytes/immunology , Disease Models, Animal , Female , Hemagglutination Inhibition Tests , Immunoglobulin A/analysis , Immunoglobulin G/blood , Influenza A Virus, H1N1 Subtype , Influenza Vaccines/administration & dosage , Interferon-gamma/metabolism , Interleukin-2/metabolism , Macaca mulatta , Male , Mice , Orthomyxoviridae Infections/prevention & control , Primate Diseases/prevention & control , Trachea/virology , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology
17.
PLoS One ; 6(12): e29255, 2011.
Article in English | MEDLINE | ID: mdl-22220209

ABSTRACT

To determine the role of innate immune responses in controlling influenza A virus replication, rhesus macaques (RM) were administered pegylated IFN-alpha prior to virus challenge. Systemic and mucosal pegylated IFN-alpha administration induced expression of the interferon-stimulated genes (ISG) MxA and OAS in the airways. RM treated with IFN-alpha 24 hours prior to influenza virus challenge had significantly lower peak vRNA levels in the trachea compared to untreated animals. In addition to blunting viral replication, IFN-alpha treatment minimized the weight loss and spike in body temperature after influenza infection of RM. These results confirm the importance of IFN-alpha induced innate immune responses in the rapid control of influenza A virus replication in primates.


Subject(s)
Influenza A virus/physiology , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacology , Macaca mulatta/immunology , Macaca mulatta/virology , Trachea/virology , Virus Replication/drug effects , Animals , Body Temperature/drug effects , Body Weight/drug effects , Humans , Immunity, Innate/drug effects , Immunity, Innate/immunology , Influenza A virus/drug effects , Influenza A virus/immunology , Influenza, Human/immunology , Influenza, Human/virology , Lung/drug effects , Lung/immunology , Lung/virology , Macaca mulatta/blood , Orthomyxoviridae Infections/blood , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , Trachea/drug effects , Trachea/immunology
18.
Vaccine ; 27(29): 3811-20, 2009 Jun 12.
Article in English | MEDLINE | ID: mdl-19406188

ABSTRACT

Safe and effective adjuvants for influenza vaccines that could increase both the levels of neutralizing antibody, including against drifted viral subtypes, and T-cell immunity would be a major advance in vaccine design. The JVRS-100 adjuvant, consisting of DOTIM/cholesterol cationic liposome-DNA complexes, is particularly promising for vaccines that require induction of high levels of antibody and T-cell immunity, including CD8(+) cytotoxic T lymphocytes (CTL). Inclusion of protein antigens with JVRS-100 results in the induction of enhanced humoral and cell-mediated (i.e., CD4(+) and CD8(+) T cells) immune responses. The JVRS-100 adjuvant combined with a split trivalent influenza vaccine (Fluzone-sanofi pasteur) elicited increased antibody and T-cell responses in mice and non-human primates compared to vaccination with Fluzone alone. Mice vaccinated with JVRS-100-Fluzone and challenged with antigenically drifted strains of H1N1 (PR/8/34) and influenza B (B/Lee/40) viruses had higher grade protection, as measured by attenuation of weight loss and increased survival, compared to recipients of unadjuvanted vaccine. The results indicate that the JVRS-100 adjuvant substantially increases immunogenicity and protection from drifted-strain challenge using an existing influenza vaccine.


Subject(s)
Adjuvants, Immunologic/pharmacology , Antibodies, Viral/blood , DNA/pharmacology , Influenza Vaccines/immunology , Liposomes/pharmacology , Orthomyxoviridae Infections/immunology , T-Lymphocytes/immunology , Vaccines, Subunit/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Body Weight , DNA/administration & dosage , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza B virus/immunology , Liposomes/administration & dosage , Macaca mulatta , Mice , Mice, Inbred BALB C , Orthomyxoviridae Infections/prevention & control , Survival Analysis
19.
J Immunol ; 180(4): 2385-95, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18250448

ABSTRACT

To determine the relationship between influenza A virus replication and innate antiviral immune responses, rhesus monkeys were given oseltamivir before influenza A/Memphis/7/01 (H1N1) challenge. We found that oseltamivir treatment significantly reduced viral replication in the trachea (p < 0.029). Further, in the trachea of both treated and untreated monkeys the mRNA levels of most innate antiviral molecules in the IFN-alphabeta pathway were dramatically increased by 24 h postinfection. However, the mRNA level of a single IFN-stimulated gene, MxA (myxovirus resistance A), the IFN-stimulated gene known to be critical in blocking influenza virus replication, was significantly lower in the tracheal lavages of untreated monkeys than in the oseltamivir-treated monkeys (p = 0.05). These results demonstrate for the first time that uncontrolled influenza A virus replication actively suppresses MxA gene expression and emphasize the critical role of innate immunity in controlling influenza virus replication in vivo.


Subject(s)
GTP-Binding Proteins/antagonists & inhibitors , GTP-Binding Proteins/biosynthesis , Influenza A Virus, H1N1 Subtype/immunology , Interferons/physiology , Orthomyxoviridae Infections/prevention & control , Trachea/metabolism , Trachea/virology , Virus Replication/immunology , Animals , Antibodies, Viral/biosynthesis , Body Temperature , Cell Line , GTP-Binding Proteins/genetics , Humans , Influenza, Human/immunology , Influenza, Human/prevention & control , Influenza, Human/virology , Macaca mulatta , Myxovirus Resistance Proteins , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , RNA, Messenger/biosynthesis , Trachea/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...